Mayaro Fever

Mayaro fever is a zoonotic, mosquito-borne viral illness caused by Mayaro virus (MAYV; species Alphavirus mayaro), an arthritogenic positive-sense single-stranded RNA virus belonging to the Semliki Forest antigenic complex within the genus Alphavirus, family Togaviridae. First isolated in 1954 from the blood of five febrile forest workers in Mayaro County, southeastern Trinidad, the disease is endemic across the humid tropical forests of the Amazon Basin, the Orinoco Basin, and the Guiana Shield, with recurrent outbreaks and sporadic human infections documented in Brazil (Pará, Amazonas, Mato Grosso, and Goiás), Peru (Loreto and Madre de Dios), Bolivia, Venezuela, Colombia, and French Guiana. Maintained primarily in a canopy enzootic cycle between acrodendrophilic mosquitoes—chiefly Haemagogus janthinomys—and arboreal non-human primates, Mayaro fever presents as a biphasic clinical syndrome characterized by an acute febrile phase mimicking dengue fever followed in 50 to 80 percent of patients by debilitating, chronic symmetric polyarthralgia and tenosynovitis closely resembling chikungunya.

Viral Structure and Phylogeographic Lineages

The Mayaro virus virion is an enveloped, icosahedral particle measuring approximately 70 nm in diameter. Its ~11.5 kb positive-sense RNA genome contains two open reading frames: a 5′ genomic region encoding four non-structural replicase proteins (nsP1, nsP2, nsP3, and nsP4) and a 3′ subgenomic 26S RNA encoding the structural polyprotein (capsid C, envelope glycoproteins E3, E2, 6K/TF, and E1). Eighty trimeric E1–E2 heterodimer spikes project from the host-derived lipid bilayer. The E2 glycoprotein mediates attachment to host cell surface receptors—including the immunoglobulin-like cell adhesion molecule MXRA8 on synovial fibroblasts, osteoblasts, and skeletal myocytes—whereas the E1 glycoprotein houses a hydrophobic class II fusion peptide that drives low-pH endosomal membrane fusion.

Phylogenetic analyses of the E1 and E2 envelope genes classify Mayaro virus into three distinct genotypes with defined geographic distributions across the Neotropics:

• Genotype D (widely dispersed): The predominant pan-Amazonian lineage circulating across Trinidad, Brazil, Peru, Bolivia, Venezuela, Colombia, and French Guiana.
• Genotype L (limited): A geographically focal lineage isolated primarily in north-central Brazil (notably Pará State and the Tocantins-Araguaia basin) and subsequently detected in Haiti.
• Genotype N (new): A sylvatic lineage identified in 2010 during febrile surveillance in the Department of Madre de Dios in southeastern Amazonian Peru.

Canopy Enzootic Cycles and Bridge Vector Spillover

In natural ecosystems, Mayaro fever is sustained through a sylvatic transmission cycle structurally parallel to the sylvatic yellow fever cycle. The primary enzootic vector is the metallic-colored, tree-hole-breeding mosquito Haemagogus janthinomys, which feeds predominantly in the forest canopy on diurnal non-human primates, including marmosets (Callithrix and Mico spp.), howler monkeys (Alouatta spp.), capuchin monkeys (Sapajus spp.), squirrel monkeys (Saimiri spp.), and two-toed and three-toed sloths (Choloepus and Bradypus spp.). Serological and virological surveys across Pará State (Brazil) and French Guiana have also identified secondary vertebrate hosts among marsupials, agoutis (Dasyprocta), and migratory birds, alongside secondary mosquito vectors in the genera Sabethes, Mansonia, Psorophora, and Culex.

Human spillover occurs primarily at the forest-agriculture ecotonal boundary when loggers, rubber tappers, gold miners (garimpeiros), ecotourists, and peri-urban settlers enter canopy or forest-edge habitats during peak daytime biting hours. Controlled laboratory vector-competence studies demonstrate that urban and peridomestic anthropophilic mosquitoes—specifically Aedes aegypti and Aedes albopictus—can become infected and transmit MAYV via saliva when human viremia exceeds 10⁴ to 10⁵ plaque-forming units per milliliter (PFU/mL), raising ongoing public health concern over potential peri-urban amplification in rapidly expanding Amazonian cities such as Manaus, Belém, and Iquitos.

Following inoculation into the dermis by an infected female mosquito, Mayaro virus replicates locally within dermal fibroblasts, Langerhans cells, and endothelial cells before draining to regional lymph nodes and establishing systemic viremia. From the bloodstream, the virus exhibits marked tropism for striated skeletal muscle, periosteal tissue, tendon sheaths, and articular synovium.

Persistent Macrophage Infection and Cytokine Cascade

The hallmark chronic arthropathy of Mayaro fever is driven by viral invasion of joint tissues and sustained innate and adaptive inflammatory signaling. MAYV directly infects synovial fibroblasts, osteoblasts, and tissue-resident macrophages. Within infected macrophages, viral replication triggers reactive oxygen species generation, mitochondrial dysfunction, and activation of the NLRP3 inflammasome, resulting in the proteolytic maturation and secretion of interleukin-1β (IL-1β) and IL-18.

In human longitudinal cohorts from Peru and Brazil, progression from acute febrile illness to chronic polyarthralgia correlates with elevated systemic and intra-articular concentrations of pro-inflammatory cytokines and chemokines—specifically interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), vascular endothelial growth factor (VEGF), and monocyte chemoattractant protein-1 (MCP-1 / CCL2). Persistent viral RNA and antigen retained within synovial macrophages continue to recruit circulating CD14⁺ monocytes and CD4⁺ T lymphocytes into the joint capsule while stimulating osteoclastogenesis and matrix metalloproteinase (MMP-2 and MMP-9) release, producing periarticular edema, tenosynovitis, and cartilage matrix degradation without frank purulent septic arthritis.

Acute Febrile and Exanthematous Phase

After an extrinsic incubation period of 7 to 12 days in the mosquito vector and an intrinsic incubation period of 3 to 11 days (mean 5 to 7 days) in the human host, Mayaro fever begins abruptly with high fever (39.0 to 40.5 °C), chills, frontal and retro-orbital headache, photophobia, dizziness, anorexia, and generalized myalgia affecting the lumbar spine and calves. Arthralgia appears within the first 24 hours of illness in more than 85 percent of symptomatic patients.

Between days 3 and 5 of illness—often coinciding with defervescence—approximately 40 to 65 percent of patients develop a non-pruritic or mildly pruritic maculopapular exanthem distributed across the trunk, extremities, and face; the rash typically fades within 3 to 4 days followed by fine desquamation. Additional acute findings include inguinal or cervical lymphadenopathy, conjunctival injection, nausea, vomiting, diarrhea, and mild mucosal bleeding (gingival oozing or epistaxis), although decompensated plasma leakage and shock characteristic of antibody-dependent enhancement in dengue are exceedingly rare. Routine hematological panels during the first week consistently demonstrate transient leukopenia (2,000–3,800 leukocytes/μL) with relative lymphocytosis, mild thrombocytopenia (90,000–140,000 platelets/μL), and modest elevations in serum aspartate and alanine aminotransferases.

Chronic Arthralgia and Tenosynovitis

While fever and systemic constitutional symptoms resolve within 5 to 7 days, 50 to 80 percent of adult patients transition into a protracted subacute and chronic rheumatologic phase lasting from 3 months to more than 1 year. The arthropathy is typically symmetric and polyarticular, preferentially affecting small and medium-sized distal joints:

• Most frequently involved joints: Wrists, metacarpophalangeal and proximal interphalangeal joints of the fingers, ankles, knees, and elbows.
• Tenosynovitis and morning stiffness: Patients experience pronounced morning stiffness exceeding 60 minutes, painful digital flexor and extensor tenosynovitis, carpal tunnel compression symptoms, and recurrent periarticular swelling that impairs manual labor and grip strength.
• Rare extra-articular complications: Isolated cases of meningoencephalitis, myocarditis, rhabdomyolysis, and anterior uveitis have been reported during verified outbreaks in Pará State and French Guiana.

Differential Diagnosis and Laboratory Confirmation

Because Mayaro fever co-circulates throughout the Amazon and Orinoco basins with dengue fever, chikungunya, Zika virus, and Oropouche fever, clinical differentiation during the first week of illness is challenging. Epidemiological surveys in Loreto (Peru), Mato Grosso (Brazil), and Bolívar State (Venezuela) indicate that 1 to 10 percent of cases clinically diagnosed as dengue or chikungunya during seasonal outbreaks are actually unrecognized Mayaro virus infections.

Definitive diagnosis relies on stage-appropriate virological and serological assays:

1. Viremic window (days 1 to 5 of fever): Detection of viral RNA in serum or plasma by real-time reverse transcription-polymerase chain reaction (RT-qPCR) targeting conserved regions of the nsP1 or E1 genes, or viral isolation in Vero or C6/36 mosquito cell cultures.
2. Serological phase (day 6 onward): IgM antibody-capture enzyme-linked immunosorbent assay (MAC-ELISA) and paired acute-and-convalescent IgG ELISA. Because MAYV shares conserved antigenic epitopes on the E1 glycoprotein with other Semliki Forest complex alphaviruses—most notably chikungunya and Una virus—positive ELISA results in co-endemic regions require confirmation by plaque reduction neutralization testing (PRNT₈₀ or PRNT₉₀), where a fourfold or greater neutralizing titer differential identifies the infecting virus.

Symptomatic Therapy and Vector Avoidance

No licensed specific antiviral agent or commercial human vaccine is currently available for Mayaro fever, although live-attenuated (MAYV/IRES), chikungunya-vectored cross-protective, and DNA/mRNA vaccine candidates have demonstrated sterilizing immunity in murine and non-human primate models. During the acute febrile phase, patients are managed with oral hydration and acetaminophen (paracetamol) while avoiding aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) until dengue fever has been excluded by laboratory testing. Once dengue is ruled out and the patient enters the post-viremic subacute or chronic arthritic phase, NSAIDs (naproxen, ibuprofen, or meloxicam), short courses of low-dose systemic corticosteroids for refractory tenosynovitis, and physical therapy are employed to restore joint mobility. Prevention centers on personal protection during forest entry using DEET- or picaridin-based repellents, permethrin-treated long-sleeved clothing, and insecticide-treated bed nets in sylvatic camps.

How is Mayaro fever distinguished clinically from dengue and chikungunya?

During the first 3 to 5 days of illness, Mayaro fever, dengue, and chikungunya present with nearly indistinguishable fever, retro-orbital headache, myalgia, rash, and leukopenia. Unlike dengue, Mayaro fever rarely causes hemoconcentration or hypovolemic shock during defervescence, and instead transitions in 50 to 80 percent of patients into persistent symmetric small-joint polyarthralgia and tenosynovitis. Because chikungunya produces an almost identical chronic arthropathy and shares antigenic cross-reactivity within the Semliki Forest alphavirus complex, definitive distinction requires acute-phase multiplex RT-qPCR or convalescent plaque reduction neutralization testing (PRNT).

Can urban mosquitoes like Aedes aegypti transmit Mayaro virus?

Laboratory vector-competence experiments confirm that both Aedes aegypti and Aedes albopictus can acquire Mayaro virus from blood meals and transmit infectious virions in saliva. In field settings, however, human viremia during Mayaro fever is typically lower and shorter in duration (lasting 3 to 5 days at 10³–10⁵ PFU/mL) than in chikungunya, which has historically restricted transmission primarily to the canopy vector Haemagogus janthinomys while leaving urban adaptation an active focus of genomic surveillance.

Why do joint pains persist for months after Mayaro fever resolves?

Chronic polyarthralgia following Mayaro fever is caused by viral persistence within joint-resident macrophages and synovial fibroblasts rather than uncontrolled systemic viremia. Retained viral RNA and antigens stimulate continuous local production of interleukin-6 (IL-6), TNF-α, MCP-1 (CCL2), and matrix metalloproteinases, driving chronic synovial inflammation, periarticular edema, and tenosynovitis of the wrists, fingers, and ankles.

1. Tesh, R. B., Watts, D. M., Russell, K. L., et al. (1999). Mayaro virus disease: an emerging mosquito-borne zoonosis in tropical South America. Clinical Infectious Diseases, 28(1), 67–73. doi:10.1086/515070
2. Powers, A. M., Aguilar, P. V., Chandler, L. J., et al. (2006). Genetic relationships among Mayaro and Una viruses suggest distinct patterns of transmission. American Journal of Tropical Medicine and Hygiene, 75(3), 461–469. doi:10.4269/ajtmh.2006.75.461
3. Halsey, E. S., Siles, C., Guevara, C., et al. (2013). Mayaro virus infection, Amazon Basin region, Peru, 2010–2013. Emerging Infectious Diseases, 19(11), 1839–1842. doi:10.3201/eid1911.130777
4. Santiago, F. W., Halsey, E. S., Siles, C., et al. (2015). Long-Term Arthralgia after Mayaro Virus Infection Correlates with Sustained Pro-inflammatory Cytokine Response. PLOS Neglected Tropical Diseases, 9(10), e0004104. doi:10.1371/journal.pntd.0004104
5. Acosta-Ampudia, Y., Monsalve, D. M., Rodríguez, Y., et al. (2018). Mayaro: an emerging viral threat? Emerging Microbes & Infections, 7(1), 163. doi:10.1038/s41426-018-0163-5
6. Diagne, C. T., Bengue, M., Choumet, V., Hamel, R., Pompon, J., & Missé, D. (2020). Mayaro Virus Pathogenesis and Transmission Mechanisms. Pathogens, 9(9), 738. doi:10.3390/pathogens9090738